BESREMi is a Subcutaneous Injection in the Human Prescription Drug category. It is labeled and distributed by Pharmaessentia Usa. The primary component is Ropeginterferon Alfa-2b.
Product ID | 73536-500_89b4913a-7822-4605-9765-2fdd0121107b |
NDC | 73536-500 |
Product Type | Human Prescription Drug |
Proprietary Name | BESREMi |
Generic Name | Ropeginterferon Alfa-2b |
Dosage Form | Injection |
Route of Administration | SUBCUTANEOUS |
Marketing Start Date | 2021-11-12 |
Marketing Category | BLA / |
Application Number | BLA761166 |
Labeler Name | PharmaEssentia USA |
Substance Name | ROPEGINTERFERON ALFA-2B |
Active Ingredient Strength | 500 ug/mL |
NDC Exclude Flag | N |
Listing Certified Through | 2022-12-31 |
Marketing Start Date | 2021-11-12 |
NDC Exclude Flag | N |
Sample Package? | N |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
BESREMI 90727699 not registered Live/Pending |
PHARMAESSENTIA CORPORATION 2021-05-21 |
BESREMI 90606528 not registered Live/Pending |
PHARMAESSENTIA CORPORATION 2021-03-26 |
BESREMI 79168468 4896895 Live/Registered |
PHARMAESSENTIA CORPORATION 2015-05-20 |